Creative Biolabs Unveils RT-LAMP-based Assays for Rapid SARS-CoV-2 Detection
New York, USA – March 21, 2022 – The Food and Drug Administration (FDA) has been taken efforts to evaluate COVID-19 related diagnostic tests ever since the pandemic beginning. Currently, over 400 COVID-19 related tests and collection kits have been authorized, including molecular tests, at-home tests and kits, and point-of-care tests. To detect SARS-CoV-2, many research groups, including Creative Biolabs, a specialist in virus screening, in vitro diagnosis, and pre-clinical research, are dedicated to developing new diagnostic assays based on various technology platforms.
Besides the gold standard for virus diagnosis, nucleic acid detection by reverse transcription quantitative PCR (RT-qPCR), loop-mediated isothermal amplification (LAMP) is another method widely used for pathogen detection. Creative Biolabs, with extensive experience in developing IVD reagents for SARS-CoV-2 and related assays, succeeds in applying the LAMP technique to SARS-CoV-2 detection.
RT-LAMP for SARS-CoV-2 is a promising technique that leads to fast, accurate detection for the SARS-CoV-2 genome in different populations, which is helpful for large-scale screening of viruses in low-resource scenarios. Creative Biolabs has established a series of RT-LAMP-based assays for the novel SARS-CoV-2 analysis and detection. The RT-LAMP assays developed by Creative Biolabs can detect potential SARS-CoV-2-affected samples as fast as 1-2 hours without highly trained staff and expensive equipment. In addition, this innovative life science company has also designed a powerful RT-LAMP platform, which can quantify and analyze samples with the minimum concentration (10-5 PFU), to identify SARS-CoV-2 susceptible populations, suggesting informative data for SARS-CoV-2 control strategies.
Creative Biolabs can not only assist RT-LAMP-based IVD kits development for rapid diagnosis of SARS-CoV-2 but also provide high-quality SARS-CoV-2 drug discovery services to help clients develop and evaluate SARS-CoV-2 drugs. It has established a panel of pre-qualified cytokine and chemokine assays to avoid additional diseases caused by SARS-CoV-2 targeted new drugs.
About Creative Biolabs
Creative Biolabs is a progressive biotechnology company passionate about empowering the field of drug discovery and vaccine development. Creative Biolabs solves real-world drug discovery problems by providing not only various products for basic research but also trustworthy services for antiviral drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic reagent development. Its extensive experience keeps it at the forefront of drug discovery and vaccine development.
For more information about Creative Biolabs and its RT-LAMP-based assays and platform for rapid SARS-CoV-2 detection and analysis, please go to: https://sars-cov-2.creative-biolabs.com.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com
